Edgen Stock·Sep 29 2025, 19:03戻る
戻る
Medincell Shares Advance Following Positive UZEDY® Clinical Data and Upgraded Revenue Outlook
Edgen Stock·Sep 29 2025, 19:03
[1] Medincell: New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna® (https://finance.yahoo.com/news/medincell-data ...)[2] Medincell's UZEDY® Gains Clinical Momentum: Implications for Market Share and Investor Value - AInvest (https://vertexaisearch.cloud.google.com/groun ...)[3] Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation (https://vertexaisearch.cloud.google.com/groun ...)